Comparing Basilea Pharmaceutica (OTCMKTS:BPMUF) & Coherus Oncology (NASDAQ:CHRS)

Basilea Pharmaceutica (OTCMKTS:BPMUF) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation.

Insider & Institutional Ownership

72.8% of Coherus Oncology shares are owned by institutional investors. 8.1% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Basilea Pharmaceutica has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500. Comparatively, Coherus Oncology has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.

Profitability

This table compares Basilea Pharmaceutica and Coherus Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Basilea Pharmaceutica	N/A	N/A	N/A
Coherus Oncology	397.30%	-198.90%	-46.65%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Basilea Pharmaceutica and Coherus Oncology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basilea Pharmaceutica	0	1	0	0	2.00
Coherus Oncology	0	1	3	0	2.75

Coherus Oncology has a consensus target price of $8.67, indicating a potential upside of 523.50%. Given Coherus Oncology’s stronger consensus rating and higher possible upside, analysts plainly believe Coherus Oncology is more favorable than Basilea Pharmaceutica.

Earnings & Valuation

This table compares Basilea Pharmaceutica and Coherus Oncology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basilea Pharmaceutica	$280.43 million	2.83	$48.57 million	N/A	N/A
Coherus Oncology	$42.17 million	5.08	$168.02 million	$1.67	0.83

Coherus Oncology has lower revenue, but higher earnings than Basilea Pharmaceutica.

Summary

Coherus Oncology beats Basilea Pharmaceutica on 9 of the 12 factors compared between the two stocks.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

About Coherus Oncology

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company’s licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.